Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B

AGIOS PHARMACEUTICALS, INC.

2021-FY EPS reported $26.55

Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.
Received FDA approval for PYRUKYND (mitapivat), first therapy for hemolytic anemia in adults with PK deficiency.
Cash, cash equivalents and marketable securities $1.3B as of Dec. 31, 2021; expects to fund operations to cash-flow positivity.
Dosed first patients in three pivotal trials of PYRUKYND in thalassemia and sickle cell disease.
R&D expenses $73.3M in Q4 2021, up from $59.4M in Q4 2020 due to pivotal study start-up costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.